1. Executive Summary 2. United States Non–Invasive Prenatal Testing(NIPT) Market Size & Analysis (2015 – 2026) 2.1 Total Actual NIPT Test Volume (Number of Tests Performed) & Forecast (2015 – 2026) 2.1.1 Average Risk Actual NIPT Test Volume (Number of Tests Performed) & Forecast (2015 – 2026) 2.1.2 High–Risk Actual NIPT Test Volume (Number of Tests Performed) & Forecast (2015 – 2026) 2.2 Total Actual NIPT Test Market Revenue & Forecast (2015 – 2026) 2.2.1 Average Risk Actual NIPT Test Market Revenue & Forecast (2015 – 2026) 2.2.2 High–Risk Actual NIPT Test Market Revenue & Forecast (2015 – 2026) 3. United States Non–Invasive Prenatal Testing(NIPT) Market Opportunity Assessment (2015 – 2026) 3.1 Total Potential NIPT Test Volume (Number of Tests Performed) & Forecast (2015 – 2026) 3.1.1 Average Risk Potential NIPT Test Volume (Number of Tests Performed) & Forecast (2015 – 2026) 3.1.2 High–Risk Potential NIPT Test Volume (Number of Tests Performed) & Forecast (2015 – 2026) 3.2 Total Potential NIPT Test Market Revenue & Forecast (2015 – 2026) 3.2.1 Average Risk Potential NIPT Test Market Revenue & Forecast (2015 – 2026) 3.2.2 High–Risk Potential NIPT Test Market Revenue & Forecast (2015 – 2026) 4. United States Non–Invasive Prenatal Testing Market Drivers and Inhibitors 4.1 Market Drivers 4.2 Market Inhibitors 5. Non–Invasive Prenatal Testing Comparative Analysis – By Test 6. Reimbursement Policies of the United States Non–Invasive Prenatal Testing 7. Regulation System of the United States Non–Invasive Prenatal Testing 8. Major Deals in the Non–Invasive Prenatal Testing Market 8.1 Collaboration Deals 8.2 Venture Capital Investment 8.3 Merger and Acquisition 8.4 Exclusive Agreement 8.5 Licensing Agreement 8.6 Distribution Agreement 8.7 Partnership Deals 9. Key Companies Analysis 9.1 Integrated Genetics (LabCorp) 9.1.1 Business Overview 9.1.2 Product Outlook 9.1.3 Key Developments 9.2 Ariosa Diagnostics (Roche) 9.2.1 Business Overview 9.2.2 Product Outlook 9.2.3 Key Developments 9.3 Illumina 9.3.1 Business Overview 9.3.2 Product Outlook 9.3.3 Key Developments 9.4 Natera 9.4.1 Business Overview 9.4.2 Product Outlook 9.4.3 Key Developments 9.5 Quest Diagnostics 9.5.1 Business Overview 9.5.2 Product Outlook 9.5.3 Key Developments 9.6 Myriad Genetics 9.6.1 Business Overview 9.6.2 Product Outlook 9.6.3 Key Developments 9.7 Centogene 9.7.1 Business Overview 9.7.2 Product Outlook 9.7.3 Key Developments 9.8 Invitae Corporation 9.8.1 Business Overview 9.8.2 Product Outlook 9.8.3 Key Developments 9.9 Otogenetics 9.9.1 Business Overview 9.9.2 Product Outlook 9.9.3 Key Developments 9.10 GenPath 9.10.1 Business Overview 9.10.2 Product Outlook 9.10.3 Key Developments 9.11 Progenity 9.11.1 Business Overview 9.11.2 Product Outlook 9.11.3 Key Developments 9.12 PerkinElmer 9.12.1 Business Overview 9.12.2 Product Outlook 9.12.3 Key Developments 9.13 Agilent Technologies 9.13.1 Business Overview 9.13.2 Product Outlook 9.13.3 Key Developments

List of Tables Table 4–1: Maternal Age at Delivery and Risk of Down Syndrome Table 5–1: Non–Invasive Prenatal Testing – Comparative Tests Analysis Table 6–1: NIPT Test CMS Price (US$),2017 Table 7–1: Collaboration Deals in the Non–Invasive Prenatal Testing Market Table 7–2: Venture Capital Investment in the Non–Invasive Prenatal Testing Market Table 7–3: Merger & Acquisition in the Non–Invasive Prenatal Testing Market Table 7–4: Exclusive Agreement in the Non–Invasive Prenatal Testing Market Table 7–5: Licensing Agreement in the Non–Invasive Prenatal Testing Market Table 7–6: Distribution Agreement in the Non–Invasive Prenatal Testing Market Table 7–7: Partnership Deals in the Non–Invasive Prenatal Testing Market List of Figures Figure 2–1: United States Actual NIPT Test Volume (Thousand),2015 – 2018 Figure 2–2: United States Actual NIPT Test Volume Forecast (Thousand),2019 – 2026 Figure 2–3: United States Average Risk Actual NIPT Test Volume (Thousand),2015 – 2018 Figure 2–4: United States Average Risk Actual NIPT Test Volume Forecast (Thousand),2019 – 2025 Figure 2–5: United States High–Risk Actual NIPT Test Volume (Thousand),2015 – 2018 Figure 2–6: United States High–Risk Actual NIPT Test Volume Forecast (Thousand),2019 – 2026 Figure 2–7: United States Actual NIPT Test Market Revenue (Million US$),2015 – 2018 Figure 2–8: United States Actual NIPT Test Market Revenue Forecast (Million US$),2019 – 2026 Figure 2–9: United States Average Risk Actual NIPT Test Market Revenue (Million US$),2015 – 2018 Figure 2–10: United States Average Risk Actual NIPT Test Market Revenue Forecast (Million US$),2019 – 2026 Figure 2–11: United States High–Risk Actual NIPT Test Market Revenue (Million US$),2015 – 2018 Figure 2–12: United States High–Risk Actual NIPT Test Market Revenue Forecast (Million US$),2019 – 2026 Figure 3–1: United States Potential NIPT Test Volume (Thousand),2015 – 2018 Figure 3–2: United States Potential NIPT Test Volume Forecast (Thousand),2019 – 2026 Figure 3–3: United States Average Risk Potential NIPT Test Volume (Thousand),2015 – 2018 Figure 3–4: United States Average Risk Potential NIPT Test Volume Forecast (Thousand),2019 – 2026 Figure 3–5: United States High–Risk Potential NIPT Test Volume (Thousand),2015 – 2018 Figure 3–6: United States High–Risk Potential NIPT Test Volume Forecast (Thousand),2019 – 2026 Figure 3–7: United States Potential NIPT Test Market Revenue (Million US$),2015 – 2018 Figure 3–8: United States Potential NIPT Test Market Revenue Forecast (Million US$),2019 – 2026 Figure 3–9: United States Average Risk Potential NIPT Test Market Revenue (Million US$),2015 – 2018 Figure 3–10: United States Average Risk Potential NIPT Test Market Revenue Forecast (Million US$),2019 – 2026 Figure 3–11: United States High–Risk Potential NIPT Test Market Revenue (Million US$),2015 – 2018 Figure 3–12: United States High–Risk Potential NIPT Test Market Revenue Forecast (Million US$),2019 – 2026